ResoTher Pharma reports Phase 2a RTP-026 results
Strong safety, tolerability, and efficacy signals support advancement to Phase 2b for severe STEMI patients.
Stay informed with the latest news and media coverage for the biggest companies in Biotechnology & Medical Research. We track all announcements, press releases, and industry mentions in real time, all in one place. Looking for another sector? Browse our industry database.
Last updated
Strong safety, tolerability, and efficacy signals support advancement to Phase 2b for severe STEMI patients.
The new device combines spectral resolution with standardization, making advanced flow cytometry more accessible for researchers in academia and pharmaceutical settings.
He joins with over 25 years of experience to lead technology and innovation efforts in clinical research.
The updated prescribing information lowers initial infusion observation from 22 hours to 6-8 hours, facilitating broader access in community oncology settings.
Unlock all announcements with a free trial
https://www.merck.com/events/morgan-stanley-24th-annual-global-healthcare-conference...
Reverse takeover company Hunter Capital RTO1 announces that Resother Pharma, the intended target in its reverse takeover project...
Reduces Equity OverhangHENDERSON, Nev., Sept. 14, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the full pre-payment ...
BioNTech said on Monday that a late-stage trial showed its drug candidate gotistobart led to a c...
Unlock all articles with a free trial
Track Every Market Move
Follow your target companies and get daily news updates delivered straight to your inbox
Start free trialBrowse the top companies in Biotechnology & Medical Research and stay on top of their latest developments.